All studies
Cardiology · EHR · UK

Althunian 2020

Atrial fibrilation

ITT, PP, ATNon-inferiorityAcademia, Government2/5 disclosures
Comparisons
3
In the analysis
3
all comparisons pooled
Target trials
1
Emulations reported
3
2 treatments

Comparisons

3 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Major bleeding
vs Rocket AF·HR·Safety
1.040.90–1.20
1.070.95–1.21
overlap0.30 SE apart
Stroke, systemic embolism, or vascular death
vs Rocket AF·HR·Efficacy
0.860.74–0.99
1.181.03–1.34
no overlapPartial alignment3.16 SE apart
Stroke, systemic emoblism prevention
vs Rocket AF·HR·Efficacy
0.880.75–1.03
1.040.84–1.30
overlap1.21 SE apart

Design and methods

Estimand
ITT, PP, AT
Design hypothesis
Non-inferiority
Matching / weighting
None
Analysis method
Cox PH
Missing data
Complete case
Covariates adjusted
32
DAG
No
QBA
No

Data and sample

Data type
EHR
Data sources
1
Geography
UK
Eligible sample
25473
Treated
4008
Control
21465
Emulations
3
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: None
Funding
Declared: Public
Funders
Saudi Food and Drug Authority (SFDA)

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2020_Althunian_AtrialFibrilation
DOI
https://doi.org/10.1002/pds.5065
Affiliations
Utrecht University, Dutch Medicines Evaluation Board, University Medical Center Utrecht
Sector
Academia, Government
Target trials (study level)
ROCKET AF
Registration
NCT00403767